Mostrar el registro sencillo del ítem
IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality
dc.contributor.author | Serrano, Antonio | |
dc.contributor.author | Garcia, Florencio | |
dc.contributor.author | Serrano, Manuel | |
dc.contributor.author | Ramirez, Elisa | |
dc.contributor.author | Alfaro, F Javier | |
dc.contributor.author | Lora, David | |
dc.contributor.author | Paz-Artal, Estela | |
dc.contributor.author | Praga, Manuel | |
dc.contributor.author | Morales, Jose M | |
dc.date.accessioned | 2024-02-06T15:16:10Z | |
dc.date.available | 2024-02-06T15:16:10Z | |
dc.date.issued | 2012 | |
dc.identifier.citation | Serrano, A., García, F., Serrano, M., Ramírez, E., Alfaro, F. J., Lora, D., de la Cámara, A. G., Paz-Artal, E., Praga, M., & Morales, J. M. (2012). IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality. Kidney international, 81(12), 1239–1244. https://doi.org/10.1038/ki.2011.477 | es |
dc.identifier.issn | 1523-1755 | |
dc.identifier.other | https://www.sciencedirect.com/science/article/pii/S0085253815552381?via%3Dihub | es |
dc.identifier.other | https://pdf.sciencedirectassets.com/313527/1-s2.0-S0085253812X79006/1-s2.0-S0085253815552381/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEPb%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJHMEUCIQCa00HyXD4UJkmBbrBKPIkHt7m34%2Bu7JhvKo9lssrzgsAIgKmF3avLCYkQX6TywEIDNiRq6HkxMyTXq7Fxw8J0rd9IqvAUIv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FARAFGgwwNTkwMDM1NDY4NjUiDK625G8OlCmy%2BAfzrCqQBascM1xNciAWVdsJvv4bPQc6KSxnxSDK29aXN7s2RH2MbAo5SwWyo4ZbiEMtSnjA2dW3q%2BPbaPK%2B%2Fl9fhVL1lqRWPoM8%2FGWb9DQFbyVH565DmiVKf9A4b4qt1e9DBgdtctvWvUF4QUmbMf0HsdaI2PF9JjxtZ36n4piypt8yh96oHHDcQdF86ZUEPumN1%2BnGq9Wegz7kB1mpi0VGzWx82hj4yMlaR6SeWKbWFfttf6tH8q%2Bg6VKAQkitMhEDm%2BRSeVxTSu%2BVxbLE0p8Qj1qiu7tVtz6%2BvLduNlrnTOaohNnyL5hgXr1jH08zPQB2pS9dm8qrQHVEQI4EZUo39rU%2BdNMaSAjwyDRxJyKImpiiW2hgOZiHNeTHOpA2TPEXjGYpx2M%2BlNNblLuSG5uPhx6C3fOPPAI%2BAoYaqERJBIUWokiomKQB1OueLqKnDuP7KhM91YUBm1p8gN%2FoH%2FD6GaFiC08G1yu7rFcCgmN%2FcI85mSYedOeaADp%2FbhfSCVsiPYI7rRmr8xF5q%2FRU3LKTQsnnm5SYdrreHmzw2KP4ujJgAlJDe3EZSfjTNrMbnw%2BAd1Ikcoll86x%2BQSK%2FH82Gei9zCZf1Ak8FGJTqLrgaCcX%2FUsjdeRgGBD5e1R%2FFvikmqVPoa7e0fjtVMH3DwrkkydCy1NGGgTIM4Ri0TO4cy%2FGdbJUg%2F7EiKdUhi2kM%2BmCwV7z0BzyNycWcWlsCV%2BTxlhwDKBq9oBpRD3ukXb6G0mLIAz2TQd1tNX%2Fpf5vAv2l%2B%2Fhn6u5cYRZw%2BggJs9Jp%2FAzV%2F6uoGMUUmjZPjxJ2NFLdgEVsqCrbUKkI750LbXTdYhUG3RfhdLeyEuWI6%2FAj%2Bz2QF4BGFYFkHylKBpDGincith5IKMMXuiK4GOrEB1o6U7bWGTWQvv4MQZIVfaaSSOzXrkiv4XoM%2FqxFjndLrXmEMgTNukc7hnR%2Bf2LFSPkAImuSZF7sV%2B4RyENjZc4ttAXdGz%2B54jW7RAm6SeeTiMyPnw5CJC%2B%2FdihmSXWiHP41t30TEF8wtTGamutIuo3eOQ6jQDqxX52f5x0iYzs29dELwZ%2Fp4NT1kh9uDiWFiChl97nAhOniQc42iJ0eakDALg%2FNAQIFyh4yOTKeEQRcr&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20240206T151428Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY6TMEB5VD%2F20240206%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=beb540ed3dd5145a7ee22632d3999318894dbaac6a1ecf3af1c76e5ece70904d&hash=0b5396982a5ca2fb1bac27facdc07565e9aa565ea4e38eac21c77f5b48f9f6c5&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0085253815552381&tid=spdf-51f7a450-c03a-4096-9c7e-bca1ab0537d6&sid=d68eb77c26c6d54c8e6bbfe9ac0c757f2fb7gxrqb&type=client&tsoh=d3d3LnNjaWVuY2VkaXJlY3QuY29t&ua=03155d5a57535a53040a&rr=851457cecbd7383f&cc=es | es |
dc.identifier.uri | http://hdl.handle.net/20.500.12020/1280 | |
dc.description.abstract | Cardiovascular complications are the most important cause of death in patients on dialysis with end-stage renal disease. Antibodies reacting with b-glycoprotein I seem to play a pathogenic role in antiphospholipid syndrome and stroke and are involved in the origin of atherosclerosis. Here we evaluated the presence of anticardiolipin and anti-bglycoprotein I antibodies together with other vascular risk factors and their relationship with mortality and cardiovascular morbidity in a cohort of 124 hemodialysis patients prospectively followed for 2 years. Of these, 41 patients were significantly positive for IgA anti-bglycoprotein I, and the remaining had normal values. At 24 months, overall and cardiovascular mortality and thrombotic events were all significantly higher in patients with high antib- glycoprotein I antibodies. Multivariate analysis using Cox regression modeling found that age, hypoalbuminemia, use of dialysis catheters, and IgA b-glycoprotein I antibodies were independent risk factors for death. Thus, IgA antibodies to b-glycoprotein I are detrimental to the clinical outcome of hemodialysis patients. | es |
dc.description.sponsorship | Fundacio´n Mutua Madrilena (2008-090), and from Fondo de Investigaciones Sanitarias (PS09-02023) | es |
dc.language.iso | en | es |
dc.publisher | Elsevier | es |
dc.title | IgA antibodies against β2 glycoprotein I in hemodialysis patients are an independent risk factor for mortality | es |
dc.type | article | es |
dc.identifier.doi | 10.1038/ki.2011.477 | |
dc.issue.number | 12 | es |
dc.journal.title | Kidney international | es |
dc.page.initial | 1239 | es |
dc.page.final | 1244 | es |
dc.rights.accessRights | openAccess | es |
dc.subject.area | Ciencias Biomédicas | es |
dc.subject.keyword | Apolipoprotein H | es |
dc.subject.keyword | Autoantibodies | es |
dc.subject.keyword | Autoimmunity | es |
dc.subject.keyword | Hemodialysis | es |
dc.subject.keyword | Mortality | es |
dc.subject.keyword | Risk factor | es |
dc.volume.number | 81 | es |